Search

Displaying results 5191 - 5200 of 10000 in total
  1. Drug

    Camponotus pennsylvanicus

    go.drugbank.com/drugs/DB14710
    Approved

    Camponotus pennsylvanicus allergenic extract is used in allergenic testing.

  2. Drug

    Eurotium amstelodami

    go.drugbank.com/drugs/DB15526
    Approved

    Eurotium amstelodami allergenic extract is used in allergenic testing.

  3. Drug

    Skim milk

    go.drugbank.com/drugs/DB15546
    Approved

    Skim milk allergenic extract is used in allergenic testing.

  4. Drug

    Field mushroom

    go.drugbank.com/drugs/DB15605
    Approved

    Field mushroom allergenic extract is used in allergenic testing.

  5. Drug

    NN-8828

    go.drugbank.com/drugs/DB18361
    Investigational

    NN-8828 is an anti-interleukin 21 monoclonal antibody.

  6. Drug

    Moricizine

    go.drugbank.com/drugs/DB00680
    ApprovedWithdrawn

    An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

    Synonyms: ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamate
  7. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  8. Drug

    Hypothiocyanite ion

    go.drugbank.com/drugs/DB15309
    Investigational

    Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).

  9. Drug

    Trelagliptin

    go.drugbank.com/drugs/DB15323
    Investigational

    Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").

  10. Drug

    LSZ-102

    go.drugbank.com/drugs/DB15362
    Investigational

    LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).